论文部分内容阅读
为探讨酸性同工铁蛋白对原发性肝癌（ＨＣＣ）的临床价值，采用ＥＬＩＳＡ－双抗体夹心法，测定４８例ＨＣＣ、３０例肝炎（ＨＰ）、２８例肝硬化（ＬＣ）患者及３３例正常人血清酸性同工铁蛋白（ＳＡＩＦ）水平。结果显示：ＨＣＣ、ＨＰ和ＬＣ组患者ＳＡＩＦ值均呈现非正态分布，其中位值分别为４４０μｇ／Ｌ、２１８μｇ／Ｌ和１２０μｇ／Ｌ，正常组为６６μｇ／Ｌ。ＨＣＣ组与其余各组比较，有显著性差异（Ｐ＜０．０５，Ｐ＜０．０１，Ｐ＜０．０１）ＨＰ与ＬＣ组和正常组比较，其差异也有显著性（Ｐ＜０．０５），但ＬＣ组与正常组比较则无显著性差异（Ｐ＞０．０５）。用ＲＯＣ确定ＳＡＩＦ＝２５０μｇ／Ｌ为临界值，则ＳＡＩＦ诊断ＨＣＣ的阳性率为８５．４６％。ＳＡＩＦ与ＡＦＰ无相关性。ＳＡＩＦ与肝癌体积和临床分期无关。以上结果表明ＳＡＩＦ有利于肝癌的早期诊断
To explore the clinical value of acid isoferritin in primary hepatocellular carcinoma (HCC), 48 patients with HCC, 30 patients with hepatitis (HP), 28 patients with liver cirrhosis (LC) and 33 patients were tested by ELISA-dual antibody sandwich method. Serum normal acid isoferritin (SAIF) levels in normal subjects. The results showed that the SAIF values in patients with HCC, HP, and LC all showed a non-normal distribution, with the median values being 440 μg/L, 218 μg/L, and 120 μg/L, respectively, and the normal group being 66 μg/L. The difference between the HCC group and the other groups was significant (P<0.05, P<0.01, P<0.01). There was also a significant difference between the HP and LC groups compared with the normal group (P<0. 05), but there was no significant difference between the LC group and the normal group (P>0.05). When the critical value of SAIF=250 μg/L was determined by ROC, the positive rate of SAIF diagnosis of HCC was 85.46%. There is no correlation between SAIF and AFP. SAIF has nothing to do with the volume and clinical stage of liver cancer. The above results show that SAIF is helpful for the early diagnosis of liver cancer